Christopher Ferreri
Overview
Explore the profile of Christopher Ferreri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
3.
Galarza Fortuna G, Banerjee R, Savid-Frontera C, Song J, Moran-Segura C, Nguyen J, et al.
Blood Cancer J
. 2024 Oct;
14(1):180.
PMID: 39414769
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and...
4.
Sidana S, Patel K, Peres L, Bansal R, Kocoglu M, Shune L, et al.
Blood
. 2024 Oct;
145(1):85-97.
PMID: 39365257
Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for...
5.
Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, et al.
Transplant Cell Ther
. 2024 Jun;
30(8):790.e1-790.e16.
PMID: 38834151
Idecabtagene vicleucel (ide-cel) has shown impressive efficacy in relapsed/refractory multiple myeloma (RRMM). This study aimed to investigate the impact of absolute lymphocyte count (ALC) on the survival outcomes of RRMM...
6.
Peres L, Oswald L, Dillard C, De Avila G, Nishihori T, Blue B, et al.
Blood Adv
. 2023 Oct;
8(1):251-259.
PMID: 37855718
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of...
7.
Hashmi H, Hansen D, Peres L, Castaneda Puglianini O, Freeman C, De Avila G, et al.
Haematologica
. 2023 Oct;
109(5):1514-1524.
PMID: 37855036
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA)...
8.
Sidana S, Peres L, Hashmi H, Hosoya H, Ferreri C, Khouri J, et al.
Haematologica
. 2023 Sep;
109(3):777-786.
PMID: 37731379
We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen receptor (CAR) T-cell therapy are unknown...
9.
Hansen D, Sidana S, Peres L, Colin Leitzinger C, Shune L, Shrewsbury A, et al.
J Clin Oncol
. 2023 Jan;
41(11):2087-2097.
PMID: 36623248
Purpose: Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa...
10.
Foster G, Grant M, Thomas S, Cameron B, Raiff D, Corbet K, et al.
Biol Blood Marrow Transplant
. 2020 May;
26(9):1597-1606.
PMID: 32450288
Despite a well-established risk of chronic kidney disease (CKD) after allogeneic hematopoietic cell transplant (allo-HCT), the benefits of using nephrotoxic anti-infective agents to treat serious peritransplant infections often outweigh this...